Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study

One of the main issues in the treatment of patients with chronic lymphocytic leukemia (CLL) deals with the choice between continuous or fixed-duration therapy. Continuous ibrutinib (IB), the first-in-class BTK inhibitor, and obinutuzumab-chlorambucil (G-CHL) are commonly used therapies for elderly a...

Full description

Bibliographic Details
Main Authors: Andrea Visentin, Francesca Romana Mauro, Gioachino Catania, Alberto Fresa, Candida Vitale, Alessandro Sanna, Veronica Mattiello, Francesca Cibien, Paolo Sportoletti, Massimo Gentile, Gian Matteo Rigolin, Francesca Maria Quaglia, Roberta Murru, Alessandro Gozzetti, Stefano Molica, Monia Marchetti, Stefano Pravato, Francesco Angotzi, Alessandro Cellini, Lydia Scarfò, Gianluigi Reda, Marta Coscia, Luca Laurenti, Paolo Ghia, Robin Foà, Antonio Cuneo, Livio Trentin
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
obinutizumab
ibrutinib
treatment-naive
MRD
economic impact
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1033413/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1033413/full

Similar Items